We demonstrated that interleukin 1 (IL-1), a potent peptide mediator in immune and inflammatory responses, stimulates the synthesis of cAMP in a variety of IL-i-responsive cell targets. We also showed that cAMP analogs and cAMP-inducing agents can replace IL-1 in the induction of interleukin 2 receptors on lymphocytes as well as in phytohemagglutinin-induced murine thymocyte proliferation. By use of IL-1 and the cAMP-inducer, forskolin, a direct correlation between the induced level of cAMP and the degree of lymphocyte interleukin 2 receptor expression or thymocyte proliferation was established. Our results indicate that cAMP may be an important intracellular second messenger for IL-1.
Interleukin 1 (IL-1), a peptide hormone produced by macrophages as well as several other cell types, stimulates the growth and differentiation of numerous cell types including lymphocytes, neutrophils, fibroblasts, synovial cells, osteoclasts, hepatocytes, and adipocytes (1-4) as well as being a potent fever inducer (5) . In addition, IL-1 has been suggested to play an important role in the pathophysiology of a variety of chronic inflammatory diseases (6, 7) .
Within the last few years, tremendous progress has been made in our understanding of the biological and biochemical properties of IL-1. Two forms of IL-1, termed a and ,B, were cloned, sequenced, and expressed (8) (9) (10) (11) (12) , and the receptor for IL-1 was characterized (13) (14) (15) . However, the events that occur after the interaction of IL-1 with its receptor have not been elucidated. Several studies have shown that IL-1 can induce the expression of interleukin 2 receptors (IL-2R) on lymphocytes (16, 17) . Recently, we reported that YT cells, a human natural killer-like cell line, possess IL-1 receptors and also increase their expression of IL-2R in response to IL-1 (18) . Therefore we chose this cell line to analyze the mechanism of IL-1 action.
MATERIALS AND METHODS Cells. All cell lines and thymocytes were cultured in RPMI 1640 medium containing 10% fetal calf serum and gentamycin at 50 ,ug/ml.
IL-1 and anti-IL-i Antibodies. Recombinant murine IL-la and human IL-la were prepared and purified as described (8, 19) . Recombinant human IL-1i8 was provided by Y. Hirai (Otsuka Pharmaceutical, Tokushima, Japan). All purified proteins migrated as single bands on sodium dodecyl sulfate/polyacrylamide gels. Neutralizing goat anti-murine IL-la IgG antibodies were prepared as described (20) . Anti-human IL-la or -,B IgG antibodies were prepared by immunization of rabbit with recombinant human IL-la or -f3 three times at 3-week intervals as described (21) . Flow Cytofluorometric Analysis of IL-2 Receptor Expression. YT cells (2 x 105 cells per ml) were incubated in RPMI 1640 medium containing 10%o fetal calf serum with or without IL-1 and various drugs at 370C for 24 hr. IL-2 receptorpositive (IL-2R+) cells were detected with a fluorescein isothiocyanate-conjugated anti-IL-2R monoclonal antibody (Becton Dickinson) and a FACS 440 flow cytofluorometer (Becton Dickinson) as described (18) .
cAMP Assay. Cells were incubated in the presence or absence of IL-1 and drugs at 37°C for varying periods. The incubations were stopped by the addition of ice-cold C13CCOOH (final concentration, 6%). The cells were then sonicated in the C13CCOOH, and the particulate material was removed by centrifugation. The Cl3CCOOH-soluble fraction was extracted once with ether before measurement of cAMP content using an RIA kit (Amersham/Searle). Cell membranes were prepared from the various cell types by hypotonic lysis in 10 mM Tris-HCl, pH 7.5, containing aprotinin (10 ,g/ml), pepstatin (1 ,ug/ml), leupeptin (1 ,ug/ml), and Na-p-tosyl-L-lysine chloromethyl ketone (50 ,ug/ml) at 4°C (30 min on ice followed by Dounce homogenization). The homogenate was centrifuged at 500 x g for 5 min at 4°C. The supernatant was recovered and recentrifuged. The nucleifree supernatant was then layered over 0.25 M sucrose and centrifuged at 15,000 x g for 30 min at 4°C. The membranecontaining pellet was resuspended in 20 mM Hepes, pH 7.2, and washed several times before use. The washed membranes were suspended in a buffer containing 20 mM Hepes, pH 7.2/50 ,uM ATP/0.3% bovine serum albumin/10 mM MgCl2/pyruvate kinase (5 ,g/ml)/4.5 mM phosphoenolpyruvate. Aliquots were incubated with or without 2.4 x 10-12 M human IL-la and 1 ,uM GTP for 10 min. Reactions were stopped by the addition of C13CCOOH. cAMP content was then measured as described above. All experiments were repeated several times with similar results.
Thymocyte Proliferation and Fractionation. The assay of C3H/HeJ mouse thymocyte proliferation (2) , Percoll gradient (density, 1.075) fractionation (22) , and characterization of subpopulations of thymocytes (22) were done as described.
Materials. The cAMP analogs, dibutyryl-cAMP and 8-bromo-cAMP, forskolin, aminophylline, and cholera toxin were purchased from Sigma.
RESULTS
Induction of IL-2 Receptors. As shown in Table 1 of cAMP. All of these agents stimulated IL-2R expression in cultures of YT cells. These observations show that an increase in the intracellular level of cAMP can trigger IL-2R expression in YT cells. Furthermore, the results suggested that the stimulatory effect of IL-1 on IL-2R expression in YT cells is mediated through an elevation in intracellular cAMP.
In contrast to our findings with agents that modify adenylate cyclase activity and cAMP levels, there was no effect of the calcium ionophore A23187 (10-9-10-5 M), calcium antagonists (e.g., diltiazem, nifedipine; 10-7-10-' M), or calmodulin inhibitors (e.g., clomipramine, prenylamine; 10-7-1105 M) on IL-1-dependent IL-2R expression in YT cells (data not shown).
Measurement ofcAMP Levels. To more directly analyze the possibility that IL-1 exerts its biological actions by means of cAMP, we measured cAMP levels in cultures of YT cells incubated with and without IL-1. Fig. la shows that purified recombinant human IL-la rapidly stimulated an increase in the intracellular level ofcAMP in YT cells. The maximal level of induced cAMP was reached after 10 min and declined to almost background levels by 120 min after stimulation. This effect of IL-1 was concentration-dependent; 50% of the maximal response being achieved with 0.04 x 10-12 M IL-la (Fig. lb) . To ensure that the cAMP-inducing activity was indeed a property of IL-1 and not some contaminating substance, we tested several preparations of purified recombinant human and murine IL-1. Recombinant human IL-la and IL-1f3 as well as recombinant murine IL-la were effective inducers of cAMP in YT cells ( Fig. 1 b-e) . Furthermore, the effect of each of these IL-1 preparations was blocked by antibodies made against each specific form of IL-1. For example, antibodies prepared against human IL-1,B inhibited the ability of human IL-1f3, but not of human or murine IL-la to enhance cAMP production. These results clearly show that the cAMP-inducing activity in the various IL-1 preparations is, indeed, a property of the IL-1 molecule itself.
Several studies have shown that IL-1 can induce the synthesis of prostaglandins (23, 24) , a class of substances known to induce cAMP production (25, 26) . We, therefore, tested whether or not the cAMP-inducing activity of IL-1 depended upon the synthesis of prostaglandins. YT cells were incubated with IL-1 with or without indomethacin, and cAMP levels were analyzed. As shown in Fig. lf , indomethacin had no detectable effect on the ability of IL-1 to induce cAMP production. Furthermore, the increase in cAMP production in response to IL-1 was also not dependent upon protein synthesis, as indicated by the observation that the protein synthesis inhibitor, cycloheximide, also had no effect on IL-1-mediated cAMP induction (Fig. 1f) .
To strengthen the connection between IL-1 induction of cAMP and IL-2R on YT cells, we examined the IL-1 concentration-dependence for both inductive events and also evaluated the concentration-dependence for forskolininduced cAMP production and IL-2R induction. As presented in Fig. 2a , the induction of cAMP and IL-2R exhibited identical patterns in terms of the concentrations of IL-1 required. Furthermore, forskolin also induced cAMP proProc. Natl. Acad duction and IL-2R expression to the same degree at each concentration tested (Fig. 2b) . With both IL-1 and forskolin, the incremental increase in the expression of IL-2R was associated with the same intracellular levels of cAMP. For example, at 6 pmol of cAMP per 2 x 106 cells, the expression of IL-2R in response to IL-1 and forskolin was =50%o. Furthermore, 2',5'-dideoxyadenosine (ddAdo), an inhibitor of adenylate cyclase (27) , markedly inhibited IL-1-induced IL-2R expression in culture of YT cells (1 mM ddAdo inhibiting IL-2R expression by =72%). These results directly correlate the intracellular concentration of cAMP with the subsequent induction of IL-2R expression by IL-1.
We next evaluated the effect of IL-1 on cAMP synthesis in isolated membrane fractions from YT cells. In the presence of GTP, cAMP production by isolated YT membranes was stimulated by IL-1 -7-fold over control membranes incubated without IL-1 ( Table 2) . Although results with YT cells were consistent with a direct link between IL-1-induced cAMP production and IL-1 action, we considered it essential to determine whether IL-1 could induce cAMP production in other types of IL-1-responsive cells. Therefore, we tested the Fig. 4a shows that the concentrations ofIL-l required for inducing cAMP accumulation and proliferation were identical, 50%o of the maximal cAMP or proliferative response occurring with -2.4 x 10-12 M IL-i. The same type of association was seen with forskolin ( Fig. 4b) (31) . In this regard, the reported inhibitory effects of dibutyryl-cAMP on T-cell receptor phosphorylation (32) (35) , several of which are also induced by IL-1, for example, c-fos, stromelysin, and plasminogen activator genes (36) (37) (38) . Examination ofthe IL-2Ra promoter (39) reveals the presence of a closely related sequence, 5'-TGACCTCA-3', at positions -945 to -938 upstream from the cap site. The possible contribution of this sequence to the regulation of IL-2R expression in response to IL-1 and cAMP remains to be determined. Nonetheless, our results provide a link between the interaction of IL-1 with its receptor and the signal-transduction pathway for IL-1-mediated cellular activation.
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